Johnson Chemical Pharmaceutical Works Co Ltd (4747) - Net Assets
Based on the latest financial reports, Johnson Chemical Pharmaceutical Works Co Ltd (4747) has net assets worth NT$1.71 Billion TWD (≈ $53.82 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.99 Billion ≈ $62.63 Million USD) and total liabilities (NT$279.70 Million ≈ $8.81 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read Johnson Chemical Pharmaceutical Works Co (4747) total liabilities for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$1.71 Billion |
| % of Total Assets | 85.93% |
| Annual Growth Rate | 12.0% |
| 5-Year Change | 98.54% |
| 10-Year Change | 107.39% |
| Growth Volatility | 24.77 |
Johnson Chemical Pharmaceutical Works Co Ltd - Net Assets Trend (2009–2024)
This chart illustrates how Johnson Chemical Pharmaceutical Works Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore how large is Johnson Chemical Pharmaceutical Works Co's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Johnson Chemical Pharmaceutical Works Co Ltd (2009–2024)
The table below shows the annual net assets of Johnson Chemical Pharmaceutical Works Co Ltd from 2009 to 2024. For live valuation and market cap data, see 4747 company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.70 Billion ≈ $53.68 Million |
+1.91% |
| 2023-12-31 | NT$1.67 Billion ≈ $52.68 Million |
+91.81% |
| 2022-12-31 | NT$871.66 Million ≈ $27.46 Million |
+2.76% |
| 2021-12-31 | NT$848.24 Million ≈ $26.72 Million |
-1.16% |
| 2020-12-31 | NT$858.20 Million ≈ $27.04 Million |
+1.21% |
| 2019-12-31 | NT$847.97 Million ≈ $26.72 Million |
+1.37% |
| 2018-12-31 | NT$836.53 Million ≈ $26.36 Million |
+0.13% |
| 2017-12-31 | NT$835.43 Million ≈ $26.32 Million |
+0.36% |
| 2016-12-31 | NT$832.41 Million ≈ $26.23 Million |
+1.32% |
| 2015-12-31 | NT$821.60 Million ≈ $25.88 Million |
+29.38% |
| 2014-12-31 | NT$635.01 Million ≈ $20.01 Million |
+8.82% |
| 2013-12-31 | NT$583.53 Million ≈ $18.38 Million |
+51.06% |
| 2012-12-31 | NT$386.30 Million ≈ $12.17 Million |
+9.31% |
| 2011-12-31 | NT$353.39 Million ≈ $11.13 Million |
+8.92% |
| 2010-12-31 | NT$324.45 Million ≈ $10.22 Million |
+4.17% |
| 2009-12-31 | NT$311.47 Million ≈ $9.81 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Johnson Chemical Pharmaceutical Works Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 450.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$90.02 Million | 5.28% |
| Other Components | NT$1.61 Billion | 94.72% |
| Total Equity | NT$1.70 Billion | 100.00% |
Johnson Chemical Pharmaceutical Works Co Ltd Competitors by Market Cap
The table below lists competitors of Johnson Chemical Pharmaceutical Works Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ci&T Inc
NYSE:CINT
|
$77.86 Million |
|
Fast Food Indonesia Tbk
JK:FAST
|
$77.87 Million |
|
Strong H Machinery Technology (Cayman) Incorporation
TW:4560
|
$77.88 Million |
|
Wanshih Electronic Co Ltd
TWO:6134
|
$77.91 Million |
|
Great Elm Capital Corp
NASDAQ:GECC
|
$77.83 Million |
|
Millie Seojae.
KQ:418470
|
$77.82 Million |
|
XL Holdings Bhd
KLSE:7121
|
$77.82 Million |
|
Fortune Parts Industry Public Company Limited
BK:FPI
|
$77.81 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Johnson Chemical Pharmaceutical Works Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,671,949,000 to 1,703,906,000, a change of 31,957,000 (1.9%).
- Net income of 84,123,000 contributed positively to equity growth.
- Dividend payments of 67,321,000 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$84.12 Million | +4.94% |
| Dividends Paid | NT$67.32 Million | -3.95% |
| Other Changes | NT$15.15 Million | +0.89% |
| Total Change | NT$- | 1.91% |
Book Value vs Market Value Analysis
This analysis compares Johnson Chemical Pharmaceutical Works Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.45x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.98x to 1.45x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | NT$27.83 | NT$55.00 | x |
| 2018-12-31 | NT$27.87 | NT$55.00 | x |
| 2019-12-31 | NT$28.25 | NT$55.00 | x |
| 2020-12-31 | NT$28.59 | NT$55.00 | x |
| 2021-12-31 | NT$28.26 | NT$55.00 | x |
| 2022-12-31 | NT$29.04 | NT$55.00 | x |
| 2023-12-31 | NT$38.29 | NT$55.00 | x |
| 2024-12-31 | NT$37.92 | NT$55.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Johnson Chemical Pharmaceutical Works Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.94%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 13.76%
- • Asset Turnover: 0.31x
- • Equity Multiplier: 1.15x
- Recent ROE (4.94%) is below the historical average (7.86%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 5.25% | 9.20% | 0.48x | 1.18x | NT$-14.81 Million |
| 2010 | 6.99% | 11.27% | 0.51x | 1.22x | NT$-9.76 Million |
| 2011 | 11.14% | 16.05% | 0.56x | 1.25x | NT$4.02 Million |
| 2012 | 12.62% | 18.30% | 0.59x | 1.18x | NT$10.12 Million |
| 2013 | 11.27% | 20.98% | 0.46x | 1.17x | NT$7.43 Million |
| 2014 | 11.27% | 19.76% | 0.48x | 1.18x | NT$8.06 Million |
| 2015 | 7.56% | 16.34% | 0.41x | 1.12x | NT$-20.03 Million |
| 2016 | 7.62% | 16.17% | 0.41x | 1.15x | NT$-19.80 Million |
| 2017 | 7.18% | 15.21% | 0.42x | 1.11x | NT$-23.53 Million |
| 2018 | 6.85% | 13.91% | 0.44x | 1.12x | NT$-26.37 Million |
| 2019 | 7.60% | 15.16% | 0.45x | 1.12x | NT$-20.33 Million |
| 2020 | 7.41% | 14.99% | 0.39x | 1.28x | NT$-22.26 Million |
| 2021 | 5.79% | 11.93% | 0.40x | 1.21x | NT$-35.72 Million |
| 2022 | 7.44% | 13.11% | 0.48x | 1.19x | NT$-22.31 Million |
| 2023 | 4.77% | 13.14% | 0.30x | 1.19x | NT$-87.49 Million |
| 2024 | 4.94% | 13.76% | 0.31x | 1.15x | NT$-86.27 Million |
Industry Comparison
This section compares Johnson Chemical Pharmaceutical Works Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,460,813,700
- Average return on equity (ROE) among peers: 6.87%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Johnson Chemical Pharmaceutical Works Co Ltd (4747) | NT$1.71 Billion | 5.25% | 0.16x | $77.86 Million |
| Grape King Bio Ltd (1707) | $1.77 Billion | 10.20% | 0.42x | $525.05 Million |
| Standard Chemical & Pharmaceutical Co Ltd (1720) | $1.58 Billion | 9.37% | 0.81x | $343.42 Million |
| Maywufa Co Ltd (1731) | $2.01 Billion | 8.19% | 0.34x | $90.66 Million |
| ScinoPharm Taiwan Ltd (1789) | $10.23 Billion | 6.44% | 0.25x | $505.73 Million |
| Lotus Pharmaceutical Co Ltd (1795) | $596.05 Million | -6.44% | 0.88x | $1.83 Billion |
| GeneFerm Biotechnology Co Ltd (1796) | $830.77 Million | 11.25% | 0.43x | $49.64 Million |
| LIWANLI Innovation Co Ltd (3054) | $783.51 Million | 0.65% | 0.06x | $167.70 Million |
| YungShin Global Holding Corp (3705) | $9.98 Billion | 11.71% | 0.38x | $466.59 Million |
| TTY Biopharm Co Ltd (4105) | $6.51 Billion | 17.35% | 0.52x | $581.27 Million |
| Phytohealth Corp (4108) | $332.05 Million | 0.00% | 0.04x | $76.66 Million |
About Johnson Chemical Pharmaceutical Works Co Ltd
Johnson Chemical Pharmaceutical Works Co., Ltd. manufactures, imports, and sells pharmaceutical ingredients, materials and products in Taiwan. The company manufactures drugs in a variety of forms, such as solid dosage form, capsule, tablet, and powder and granule, as well as nasal spray forms. It offers its products in various therapeutic areas, including central nervous system, respiratory, card… Read more